Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.

Jérémy Dufloo; Ludivine Grzelak; Isabelle Staropoli; Yoann Madec; Laura Tondeur; Francois Anna; Stéphane Pelleau; Aurelie Wiedemann; Cyril Planchais; Julian Buchrieser; Rémy Robinot; Marie-Noëlle Ungeheuer; Hugo Mouquet; Pierre Charneau; Michael White; Yves Lévy; Bruno Hoen; Arnaud Fontanet; Olivier Schwartz; Timothée Bruel.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-20230508

Documentos relacionados

  1. Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.
  2. SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines.
  3. Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients.
  4. Potent antibody-dependent cellular cytotoxicity of a V2-specific antibody is not sufficient for protection of macaques against SIV challenge.
  5. Natural Killer Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Against SARS-CoV-2 After Natural Infection Is More Potent Than After Vaccination.
  6. Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2.
  7. Antibody-Recruitment as a Therapeutic Strategy: A Brief History and Recent Advances.
  8. Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.
  9. SARS-CoV-2 Accessory Protein ORF8 Decreases Antibody-Dependent Cellular Cytotoxicity.
  10. SARS-CoV-2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice.